News

This page provides links to important reports, publications, conferences and funding opportunities related to infection, antimicrobial resistance, novel antibiotics such as bacteriocins, bacteriophage therapy and photoantimicrobial therapy


February 2017

  • Variation in P.aeruginosa virulence-associated secretions can lead to high virulence sub-populations in CF patients (link)
  • Type VI secretion system kills local bacterial competitors and favours the evolution of cooperation with kin (link)
  • The bacteriocin Listeriolysin S modifies the host microbiota during L.monocytogenes infection (link)
  • Interesting review of the role of DNA sequencing in infection control and the remaining challenges to be overcome (link)
  • Bet-hedging by single E.coli cells producing colicins to balance the cost of production and the killing of competitors (link)
  • UK study finds an average of 13 antibiotic resistance genes in the gut microbiome of healthy preterm infants (link)
  • Important findings that bacterial competition in polymicrobial infections can affect phage therapy outcomes (link)
  • US animal study indicates prophylactic potential of a cocktail of three virulent bacteriophages to prevent cholera (link)
  • Some current practices for preparing faecal microbiota implants adversely affect living microbial content (link)
  • Comprehensive review of the potential of C.difficile cell envelope components as therapeutic targets (link)
  • UK study shows transmission of S.aureus from healthcare workers to ICU patients is infrequent  (link)
  • Surprise that doxycycline resistance can result in increased E.coli growth rates (link)

January 2017

  • Impressive study on effect of hospital room disinfection on patient acquisition of infections (link)
  • Valuable prediction model for all cause 30 day mortality in ESBL-producing Enterobacteriaceae BSI patients (link)
  • Bacteriophage can talk to each other by using quorum sensing to switch from lysogenic to lytic cycle (link)
  • Surprising location-specific sequence variation in Stentotrophomonas maltophilia isolates in human lung (link)
  • A contrarian view from France: antibiotic resistance is not going to kill us all, yet!  (link)
  • What happens to antibiotic resistance genes during sewage treatment is reported in this Chinese study (link)
  • Low level phage predation promotes biofilm formation in S.aureus - has implications for phage therapy 
  • Phage-derived protein induces platelet activation and mortality in patients with invasive pneumococcal disease (link)
  • GerG, a gel-forming protein in C.difficile required for spore germination may be a promising therapeutic target (link)
  • Phage therapy: Atomic force Microscopy used to visualize the interaction of phage and UPEC in real time 
  • Interesting article entitled Resistance diagnosis and the changing economics of antibiotic discovery highlights the importance of Point of Care diagnostics for antibiotic profitability and assisting the drive for narrow spectrum agents (pdf) 
  • The review article entitled Quorum Sensing Regulation of Competence and Bacteriocins in Streptococcus pneumoniae and mutans reports a direct interaction between  ComCDE which regulates competence and the BlpRH pathway regulating bacteriocin production (link)
  • Excellent short review from my Nottingham colleagues entitled Predatory bacteria: Moving from Curiosity Towards Curative that highlight progress with the two major predatory bacteria Bdellovibrio bacteriovirus and Micavibrio aeruginovirus (link)
  • Phage lysin PlySs2 in combination with gentamycin has high activity against multiple serotypes and strains of Streptococcus suis, a significant pathogen of pigs which can be transmitted to humans (link)
  • Interesting UK study that evaluated the clinical impact of direct identification of micro-organisms from positive blood cultures using MALDI-ToF (link)
  • A three-year, single centre cohort study showed that faecal microbiota transplantation (FMT) cured 97% of patients with recurrent Clostridium difficile infection (link)
  • Study suggests that 460nm blue light irradiation kills both planktonic and biofilm MRSA via activation of prophages (link)
  • Interesting study of English hospital data concluded that outsourcing cleaning increased MRSA incidence (link)
  • A study of the killing of S.aureus and MRSA by carbon dots showed that 808nm laser irradiation accelerated cell killing and formation of reactive oxygen species and protein leakage (link)
  • US FDA approves 22 new drugs in 2016; one of which is to prevent recurrent C.difficile infections; two to treat HepC infections, but no new antibiotics (link)

December 2016

  • A review entitled CRISPR-Cas9 technology: applications in genome engineering, development of sequence-specific antimicrobials, and future prospects concludes that improved methods to deliver sequence-specific antimicrobials into bacterial cells are required (link)
  • Excellent article entitled Past, Present, and Future of Antibacterial Economics: Increasing bacterial resistance, Limited Antibiotic pipeline, and Societal Implications by Luepke, KH et al (link)
  • A recent study assessed the effectiveness of whole genome sequencing (WGS) detection of resistance genes in correctly predicting resistance phenotypes in E.coli strains. WGS detected more resistance genes than PCR but some of them were not expressed (link)
  • Encouraging data from an animal model in a paper entitled Synergistic interaction between phage therapy and antibiotics clears Pseusomonas aeruginosa infection in endocarditis and reduces virulence (link)
  • The odds of dying within 14 days were >4 times higher for patients with carbapenemase-producing Enterobacteriaceae bacteraemia than a non-carbapenamse-producing bacteraemia (link)
  • The results of a recent Dutch study of a host-protein based assay to differentiate between bacterial and viral infections in preschool children shows promise but needs further validation and cost-benefit analysis (link)
  • Wonderful and surprising story that a single phage that binds to an efflux pump protein receptor managed to eradicate a single Pseudomonas aeruginosa infection and saved an an 80 years old man's life (link)
  • Interesting photoantimicrobials paper entitled Novel polymeric nanoparticles targeting the lipopolysaccharides of Pseudomonas aeruginosa by Long et al uses molecularly imprinted nanoparticles that show specific binding to P.aeruginosa lipopolysaccharide to deliver the photosensitizer methylene blue and kill the bacterial cells (link)
  • A genome sequencing study has demonstrated the presence of multiple variants of Enterobacteriacea producing carbapenemase in one 82 year old patient (link)
  • A Danish study concluded that bacteraemia caused by a Staphylococcus aureus PVL-positive strain results in a significantly increased risk of mortality especially in individuals older than 55 years (link)
  • A review entitled Dissemination of Clostridium difficile in food and the environment: Significant sources of C.difficile community-acquired infection? by Warriner et al considers the role of food as a source of C.difficile infections (link)
  • Carocin D is a bacteriocin produced by Pectobacterium carotovorum subsp. carotovorum Pcc21, the causative organism of soft rot disease that leads to severe economic losses. Unusually Carocin D, which is a DNase-type bacteriocin, uses OmpF as a receptor and is translocated by the TonB system (link)
  • Streptococcus salivarus K12 (BLIS K12) is a probiotic strain producing the bacteriocins salivaricin A2 and salivaricin B, both of which strongly antagonize the growth of Streptococcus pyogenes, the most important bacterial cause of pharyngeal infections in humans. This study found that daily use of BLIS K12 resulted in a 90% reduction in pharyngeal disease in children (link)
  • Interesting choice as chair of the expert advisory board to support the £50 million UK Global Antimicrobial Resistance Innovation Fund (link)

November 2016

  • A useful review by da Cuhna et al. outlines recent advances in the development of novel antimicrobial peptides through structural design (link)
  • A review entitled Phage therapy in Bacterial Infections Treatment: One Hundred Years After the Discovery of Bacteriophages by Cisek et al. discusses the four phases in the history of phage therapy. (link
  • The book entitled The Bacteriocins: Current Knowledge and Future Prospects edited by Rob Dorit, Sandra Roy and Peg Riley has been published by Caister Press (link). I was honoured and humbled when the editors dedicated this book to my research on bacteriocins, and I was also very pleased to be asked to write the Preface to the book.
  • An excellent discussion of photoantimicrobials as alternatives to conventional antibiotics (link)
  • The 2016 English surveillance programme for antimicrobial utilization and resistance (ESPAUR) has been published. (link)

October 2016

  • A report entitled Clinical trials networks for antibiotic development has been published by The Wellcome Trust (link)
  • An article entitled An assessment of the future impact of alternative technologies on antibiotics markets by Nwokoro et al concludes that it is unliklely that alternative antibiotics will be a disincentive to antibiotic developers or displace the need for new classes of antibiotics in the short and medium terms. The optimism that new antibiotics will be discovered may well be misplaced and the dismissal of the benefits of narrow spectrum antibiotics combined with rapid POC diagnostics is very surprising (link)
  • UK-South Africa Antimicrobial Partnership Awards scheme announced by the MRC in partnership with the South African Medical research Council will offer 8 awards of about £80k in one of the following areas of AMR research; new drugs for Gram negative bacteria; rapid POC diagnostic tests for Gram negative pathogens; new technology for improved surveillance (link)
  • Evidence that acquisition of ESBL-producing Enterobacteriacaea associated with foreign travel is substantial and worrying (link)
  • Interesting paper entitled Enterocin A mutants identified by saturation mutagenesis enhance potency towards Vancomycin-resistant Enterococci by McClintock et al. (link)
  • Thought provoking review on phage therapy from Andrzej Gorski's laboratory in Poland  (link)

September 2016

  • Potentially interesting idea to use peptide-conjugated phosphorodiamidate morpholino oligomers (PPMO) as synthetic DNA/RNA mimics to target the AcrAB-TolC efflux system as a major intrinsic resistance mechanism in E.coli. In vitro experiments demonstrated a 2 to 40 fold increase in antibiotic efficacy when used in combination with a acrA-PPMO (link)
  • Historic event as 193 world leaders endorse the need for action to counter the threat of antimicrobial resistance at a meeting organised by the President of the United Nations General Assembly (link)
  • A novel therapeutic strategy to de-colonize antibiotic-resistant enterococci from the GI tract of patients using Enterococcus faecalis encoding the bacteriocin Bac-21 is suggested in a new study (link)
  • The UK Government response to the final report of the Review on Antimicrobial Resistance led by Lord Jim O'Neill promises to implement the recommendations Lord O'Neill has made. In particular the Government strongly support the recommendation to use global financing systems to reinvigorate early-stage research, and the development of new drugs (link)
  • High tech cinematography and a giant petri-dish allow the visualization of the development of antibiotic resistance by the accumulation of mutations in a Harvard study (link)
  • NIH announce a $20 million Prize for innovative diagnostic tests that detect and distinguish antibiotic resistant bacteria (link)
  • There is a growing consensus of the desirability of developing narrow spectrum antibiotics to reduce collateral damage to the gut microbiome during therapy, however this requires the parallel development of rapid diagnostic tests. A recent paper by Sabine Dittrich et al describes an interesting Expert Consensus approach to the development of  target product profile for a diagnostic assay to differentiate between bacterial and non-bacterial infections and reduce antimicrobial overuse (link)

August 2016

  • Positive results in a study to evaluate the therapeutic efficacy of monophage in comparison to phage cocktail in resolving the course of burn wound infection in mice (link)
  • A paper entitled Antibiotic resistance: a physicist's view claims that 'A physics-like' approach has a role to play in many aspects of AMR  and highlights three areas where such physics-like approaches are already proving successful (link)
  • Kings Fund report by Professor Dame Sally Davies and Rebecca Sugden in the series 'The NHS if' entitled What if antibiotics were to stop working?  published (link)
  • This article reports the identification of the OmpA extracellular loop 1 as the target for colicins U and Y in E.coli and for colicin U in Shigella (link)
  • Interesting paper describing the use of E.coli 83972 to establish a asymptomatic bacteriuria as a novel strategy to prevent recurrent UTI (link)

July 2016

  • This article introduces CARB-X, a new global public-private partnership that will invest >$350 million in the next 5 years to accelerate progression of a diverse portfolio of innovative antibacterial products into clinical trials (link)
  • Lots of media interest in this article which describes the identification of a new antibiotic active against S.aureus from nasal S.lugdunensis isolates (link)
  • Exciting data from Dan Walker and collaborators entitled Efficacy of species-specific protein antibiotics in a murine model of acute Pseudomonas aeruginosa lung infection (link)
  • informative review on Antimicrobial photodynamic inactivation and its future in the face of the unrelenting increase in antimicrobial resistance by Michael Hamblin (link)
  • The X-ray structure of the DNase colicin E9 in complex with its immunity protein Im9 has been determined by Colin Kleanthous and colleagues, allowing a comparison with the previously published structure of the RNase colicin E3 bound to Im3 and two DNAse pyocins, S2 and AP41. (link)
  • Phage therapy with broad host range phages is reported to be successful in a mouse model of Pseudomonas aeruginosa equine keratitis (link)
  • Interesting findings in the paper entitled  Coordinated Bacteriocin Expression and Competence in Streptococcus pneumoniae Contributes to Genetic Adaptation through Neighbor Predation suggest a regulatory link between competence and bacteriocin production that facilitates incorporation of new genetic material (link)
  • A chimeric enzyme comprising the enzymatically active domain of the autolysin LytM from S.aureus and the cell wall binding domain from the bacteriocin lysostaphin displayed potent activity in a range of environmental conditions (link)

June 2016

  • Am essay entitled Delinking Investment in Antibiotic Research and Development from Sales Revenue: The Challenges of Transforming a Promising Idea Into Reality discusses the pros and cons of proposed methods to fix the broken antibiotic discovery system (link)
  • Indications that a giant KTN4 phage is a suitable candidate for in vivo phage therapy evaluation for Pseudomonas aeruginosa lung infections (link)
  • Support for the role of CRISP and Restriction-Modification systems in preventing acquisition of antibiotic resistance plasmids in Enterococcus faecalis is provided in a paper by Price, Huo, Sharifi and Palmer (link)
  • A review entitled "Supramolecular Antibiotic switches: A Potential Strategy for Combating Drug Resistance" discusses the concept of antibiotics that can be switched on when needed through host-pathogen interactions as a means to reduce the selection for resistance  (link)
  • Interesting review of therapeutic strategies that target the virulence factor of bacterial pathogens by Brannon and Hadjifrangiskou (link)
  • Combinations of temperate phages showed promising activity against C.difficile in vitro and in vivo (link)
  • The potential of pyocin SD2 as an alternative to antibiotics for treating P.aeruginosa infections is revealed in a collaboration between laboratories in Sydney, Australia and Glasgow, UK (link

May 2016

  • Very challenging article entitled Resistance Fighters which suggests using low doses of antibiotics to hold bacteria in check and let the immune system mop up the infection in order to reduce selection for resistance (link)
  • Interesting Programme of talks on Alternatives to antibiotics in Loughborough on June 16th that includes antimicrobial peptides, antitoxins, bacteriocins, phage, resistance breakers, and vaccines (link)
  • A phage that binds to an eflux pump responsible for resistance to some antibiotics in P.aeruginosa has been identified in a Connecticut pond. The presence of the virus reduces the level of antibiotic resistance and makes the P.aeruginosa susceptible to several antibiotics (link)
  • A Phase 2 randomised, placebo-controlled trial of oral T4 phage therapy unfortunately concluded that it was no more effective than oral rehydration therapy (link)
  • The last of the excellent series of AMR reviews led by the economist Lord O'Neill has been published (link). I would like to think that throwing billions at the problem of AMR would provide the solution but I have serious doubts unless a way to reduce the $1 billion costs of developing a single antibiotic can be found.
  • A bacteriocin produced by epidemic Listeria strains alters the host intestinal microbiota to favour infection (link)
  • Bactofencin, a broad spectrum bacteriocin produced by gut isolates of Lactobacillus salivarius, has a subtle influence on intestinal communities with a potentially positive impact on anaerobic popuations (link)
  • The colicin E7 immunity protein (Im7) has been used to study the function of ATP-independent chaperones in E.coli. It is remarkable that Im7 folds into its native state whilst bound to the chaperone. (link)
  • The Pew Trust issues a Scientific roadmap for antibiotic discovery (link)
  • Interesting evidence that a bacteriocin produced by an epidemic Listeria monocytogenes strain alters the host intestinal microbiota to favour infection (link)

April 2016

  • I contributed to an article in New Scientist April 30 edition by Penny Sarchet entitled Antibiotics apocalypse: Tales from fighters on the front line  (link)
  • Interesting article entitled Use of bacteriophage to target bacterial surface structures required for virulence: a systematic search for antibiotic alternatives by Paul Orndorff discusses the use of phage resistant, attenuated mutants to screen for small molecules that block functional phage receptor assembly (link)
  • Review entitled Bacteriocins from lactic acid bacteria and their applications in meat and meat products by Woraprayote et al. discusses the direct application of bacteriocins as a food additive and incorporation of bacteriocins in packaging (link)
  • Congratulations to Lloyd Czaplewski and co-authors for the award of the Atlas Prize for their AMR review (link)
  • Thought provoking review of engineered bacteriophage technologies by Braff, Shis and Collins entitled Synthetic biology platform technologies for antimicrobial applications (link)
  • Excellent review by Egan et al on the use of bacteriocins alone and in combination with other processing methods to control spores in food (link)
  • A framework is proposed for classifying the antibiotic response of bacterial strains in Distinguishing between resistance, toleance and persistence to antibiotic treatment (link)
  • DRAMP is database of antimicrobial peptides containing information on MIC value against target organisms and structure information on 17349 sequences, including 263 bacteriocins (link)
  • New guidelines for Antibiotic Stewardship issued by IDSA and SHEA (link)
  • New funding opportunity from the CDC and the Office of the Associate Director for Science in the area of antibiotic resistance, surveillance, epidemiology and genomics (link)
  • The origins of the increasingly used term "antibiotic apocalypse" are discussed in this article (link)
  • UK Chancellor warns that antimicrobial resistance will be a greater threat than cancer by 2050 in an article in The Guardian (link)
  • Public Health England has launched a new online data resource -AMR Local Indicators Profile that are intended to raise awareness of AMR and to facilitate the development of local action plans. Data are available in five domains (antimicrobial resistance, antibiotic prescribing, healthcare associated infections, infection prevention and control, and antibiotic stewardship). The profile comprises a set of interactive tables, charts and maps, illustrating trends and regional variations in a number of AMR-related indicators for each of the domains. Data can be viewed at several geographical levels including GP practice (link)
  • Interesting review by Lee and Behr entitled The implications of whole genome sequencing in the control of tuberculosis (link)

March 2016

  • Interesting data showing a 7.9% reduction in antibiotic prescribing between April and December 2015 by NHS England compared with the same period the year before following the introduction of incentive payments in April 2015 (link).
  • Thought-provoking paper by Rex and Outterson entitled Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach (link)
  • The latest UK Review on Antimicrobial resistance report is published entitled Infection Prevention, Control and Surveillance: Limiting the Development and Spread of Drug Resistance (link)
  • Latest in series of excellent Guardian articles on AMR on the 61st anniversary of Alexander Fleming's death entitled "Antibiotic resistance is not theoretical: the threat is real and immediate" (link)
  • Excellent article by Alison Moodie in The Guardian highlighting the effects of antibiotic resistance on healthcare, food production and tourism (link)
  • The complexity of the process by which colicins are induced by DNA damage is described in The Use and Abuse of LexA by Mobile Genetic Elements by Fornelos, N. .et al Trends in Microbiology (link)
  • A disturbing picture of the scale of the problem of antibiotic resistance in India highlights the need for improved regulation of drug production and sales, better management of physician compensation, and encouraging behaviour change among doctors and patients (link)
  • Interesting summary of a paper that offers considerable hope that resistance to S-type pyocins that target siderophore receptors in P.aeruginosa may be difficult to evolve during treatment in patients (link)
  • Interesting interactive world maps of the incidence of antimicrobial resistance in a number of key bacterial pathogens produced by the Centre for Disease Dynamics, Economics, and Policy, Washington DC (link)
  • BLIS Technologies Ltd (New Zealand) have developed probiotic products for throat health, halitosis and probiotic support for the body that are  based on bacteriocins discovered by Professor John Tagg, University of Otago, New Zealand (link)

February 2016

  • Excellent review commissioned  by the Wellcome Trust and led by Lloyd Czaplewski and Jon Rex entitled "Alternatives to antibiotics-a pipeline portfolio review" in Lancet Infectious Diseases 16:239-251 (2016)
  • The World Antimicrobial Resistance Congress US 2016 will be held on September 14-15 in Washington DC (link)
  • Interesting paper on discovery of an S-type pyocin S6 that has ribonuclease activity from a Pseudomonas aeruginosa clinical isolate. Pyocin S6 shares two domains with pyocin S1 and the killing domain with colicin E3, illustrating the significance of domain shuffling in bacteriocin evolution (link)
  • The UK Review on Antimicrobial Resistance chaired by Lord Jim O'Neill produced its latest review entitled Vaccines and alternative approaches: reducing our dependence on antimicrobials (link) 
  • ClinicalTrials.gov lists; (A) Sixteen trials of bacteriophage therapy to treat infections, six of which are open (link); (B) One interventional study which is not yet open for recruitment to determine if Streptococcus salivarus BLIS K-12 prevents streptococcal throat infection in children that have had an episode of rheumatic fever 

January 2016

  • A Randomized Trial of Oral Phage Therapy of Acute Bacterial Diarrhoea with Two Coliphage Preparations failed to achieve intestinal amplification and to improve diarrhoea outcome (link)
  • NIAID awards more than $5M to fund 24 research projects seeking  to develop non-traditional antibiotics. The awards included projects involving bacteriocins targeting Clostridium difficile and bacteriophage targeting a range of pathogens including Pseudomonas aeruginosa, Enterobacteriaceae, Enterococci, MDR pathogens, and Klebsiella pneumoniae (link)
  • Interesting paper discussing the role of nutrient-poor natural environments in selecting for antibiotic resistance (link)
  • The UK Department for International Development published details of the £1 billion Ross Fund which aims to develop, test and deliver a range of new products (including vaccines, drugs and diagnostics) to help combat the world's most serious diseases in developing countries (link to pdf). 
  • Nomad Bioscience received a formal 'no question' letter from FDA in response to their GRAS notice GRN593 describing the use of colicins for control of major foodborne pathogenic strains of E.coli on vegetable foods. This is the first regulatory approval for use of a large protein antibiotic and may be the forerunner of a number of similar applications (link to pdf)
  • The long awaited book The Bacteriocins: Current Knowledge and Future Prospects edited by Rob Dorit, Sandra Roy and Peg Riley is now being advertised for sale with a publication date of July 2016 (link).

December 2015

  • Group B colicins are released into the environment but, unlike group A colicins, lack an identified colicin-specific release protein that facilitates release of the colicin. A recent paper proposes a new mechanism for the release of Group B colicins that is mediated by temperate, lambdoid phages (link)
  • China-UK AMR Partnership Initiative launched with a deadline for applications of March 1st 2016 (link)
  • A systematic analysis examining public funding for research on antibacterial resistance in the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) countries, the European Commission, and related European agencies was published (link)
  • The UK Review on Antimicrobial Resistance chaired by Lord Jim O'Neill produced its latest review entitled Antimicrobials in Agriculture and the Environment: Reducing Unnecessary Use and Waste (link)

November 2015

  • See my Commentary article on Antimicrobial resistance published in The Guardian newspaper on 21/11/15 (link).
  • Pheromonicins: an ecologically sound family of bacteriocin-based antibiotics for use in the age of the microbiome. Xiao-Qing Qiu, Sandra M Roy, and Margaret A Riley Future Microbiology 10, 1969-1979 (2015)
  • The UK Review on Antimicrobial Resistance chaired by Lord Jim O'Neill produced its latest review entitled Safe, Secure and Controlled: Managing the Supply Chain of Antimicrobials (link)

October 2015

  • Addressing Antibiotic Resistance - A Report from the Joint APLU/AAVMC Task Force on Antibiotic resistance in Production Agriculture was published (link)
  • The invitation only 2015 International Workshop on The Pheromonicin Drug development Platform organized by Xiaoqing Qiu and Peg Riley was held in Beijing, China from October 19th to 21st.
  • The UK Review on Antimicrobial Resistance chaired by Lord Jim O'Neill produced its latest review entitled Rapid Diagnostics: Stopping Unecessary Use of Antibiotics (link)
  • A report entitled Towards a New Global Business Model for Antibiotics: Delinking Revenues from Sales has been published by Chatham House (link

September 2015

  • Submission by Phagelux for a GRAS notfication for the bacteriophage cocktail SalmoPro containing bacteriophages BP-63 and BP-12, for bio-control of Salmonella enterica in food (link)
  • UK Spending Review and Autumn Statement announces a new £1 billion global fund to speed up the development of vaccines and drugs to eliminate the world’s deadliest infectious diseases.
  • Interesting paper by Schulz, S. et al. on the control of major foodborne pathogenic strains of E.coli by colicins (link)

August 2015

  • Nomad Bioscience GmbH, Halle, Germany filed a USA FDA GRAS notice GRN593 describing the use of colicins for control of major foodborne pathogenic strains of E.coli on vegetable foods.

July 2015

  • An interesting paper indicating that a Nisin ZP, a naturally occurring variant of the antimicrobial peptide nisin shows antitumour activity against head and neck cancer in a mouse model (link)
  • An interesting paper from Dan Walker's laboratory entitled Activity of Species-specific Antibiotics Against Crohn's disease-Associated Adherent-invasive Escherichia coli (link)
  • National Institute of Allergy and Infectious Diseases (NIAID) organise a Workshop entitled Bacteriophage Therapy: An Alternative Strategy to Combat Drug Resistance (link)

May 2015

  • The UK Review on Antimicrobial Resistance chaired by Lord Jim O'Neill produced its latest review entitled Securing New Drugs For Future Generations: The Pipeline of Antibiotics (link)

April 2015

  • ImmuCell announces an exclusive option agreement to license new technology concerning bacteriocins with activity against Gram negative infections for use in combatting mastitis in dairy cattle developed by Professor Margaret (Peg) Riley of the Department of Biology, University of Massachusetts Amherst

March 2015

  • Interesting paper from AvidBiotics Corp on engineering of an R-type Pyocin to target Clostridium difficile (link), although the serotype specificity of R-type pyocins will be a challenge to produce an effective therapeutic agent.

February 2015

  • The UK Review on Antimicrobial Resistance chaired by Lord Jim O'Neill produced its latest review entitled Tackling a Global health crisis: Initial Steps (link)

January 2015

  • President Obama's 2016 US FY 2016 Budget doubles the amount of federal Funding for combating and preventing antibiotic resistance to more than $1.2 billion. highlights include the development of an antibacterial resistance clinical trial network for rapid testing of new drugs to treat multi-drug resistant bacteria (link)
  • Intralyt